STOCK TITAN

Cingulate (CING) SEC Filings, Mar-May 2026

CING NASDAQ

Cingulate Inc. filings document a clinical-stage biopharmaceutical issuer developing Precision Timed Release™ drug-delivery products, including CTx-1301 for ADHD, alongside its common stock and warrants listed on Nasdaq. Periodic and current reports furnish operating results, business updates, patent notices, FDA-related program disclosures and research-and-development spending context.

The filing record also covers capital-structure actions such as private placements, preferred stock, warrants, unregistered equity issuances, debt exchanges and at-the-market offering agreements. Proxy and 8-K disclosures address shareholder voting matters, Nasdaq rule compliance, board committee composition, officer appointments, employment agreements and other governance events.

Rhea-AI Summary

Cingulate Inc. reported that EVP and CSO Raul R. Silva received a grant of stock options covering 3,422 shares of common stock. The options have an exercise price of $6.21 per share, were granted at no purchase cost, and expire on March 31, 2036. The award was made pursuant to Dr. Silva's Employment Agreement, as amended, and reflects equity-based compensation rather than an open-market share purchase or sale.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.88%
Tags
insider
-
Rhea-AI Summary

Cingulate Inc. is registering up to 4,208,711 shares of its common stock for resale by selling stockholders. The shares consist of (i) 2,147,472 issued common shares, (ii) 191,824 shares issued upon conversion of Preferred Stock, and (iii) 1,869,415 shares issuable upon exercise of a warrant. The company will receive no proceeds from resales by the selling stockholders; however, cash exercise of the warrant could yield approximately $9.4 million to the company. The prospectus discloses a Private Placement that raised approximately $12.0 million in aggregate gross proceeds and includes standard lock-up and standstill provisions for the purchasers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.64%
Tags
prospectus
-
EFFECT
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.84%
Tags
other
Rhea-AI Summary

Cingulate Inc. registers up to 4,208,711 shares of common stock for resale by selling stockholders. The registration covers shares issued in a January 27, 2026 private placement, consisting of 2,147,472 issued common shares, 191,824 shares issued upon conversion of Preferred Stock and 1,869,415 shares issuable upon exercise of a warrant.

The company will receive no proceeds from resales by the selling stockholders; however, if the warrant is exercised for cash in full, Cingulate would receive approximately $9.4 million, which it intends to use for regulatory approval and development, manufacturing and commercialization of CTx-1301 and for general corporate purposes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.80%
Tags
registration
-
Rhea-AI Summary

Cingulate Inc. appointed Zhanpeng “Frederick” Jiang to its Board of Directors as a Class I director effective March 27, 2026. He will serve until the 2028 annual meeting of stockholders, subject to earlier departure under standard conditions and terms linked to a previously filed securities purchase agreement.

Mr. Jiang joins the Audit, Compensation, and Nominating and Corporate Governance Committees, each of which has been reconstituted to include him. The Board determined he is independent under Nasdaq Listing Rule 5605, which is important for committee composition and corporate governance standards.

Under the Non-Employee Director Compensation Program, Mr. Jiang received an option to purchase 15,000 shares of common stock at the Nasdaq last reported sale price on the grant date. The option vests in two equal installments over one year. He will also receive annual cash retainers totaling $56,500 for Board and committee service.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.98%
Tags
current report
-
Rhea-AI Summary

Cingulate Inc. registers for resale up to 3,500,000 additional shares of common stock to be offered by Lincoln Park Capital Fund, LLC under a purchase agreement providing up to $25.0 million of committed equity financing.

The registration covers shares the company may elect to issue and sell to Lincoln Park under a July 21, 2025 Purchase Agreement; the company will control timing and may receive proceeds only if it sells Purchase Shares to Lincoln Park. Shares outstanding were 11,594,679 as of March 13, 2026; the prospectus shows an illustrative post-issuance count of 15,094,679 assuming sale of all 3,500,000 additional shares.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.61%
Tags
prospectus
Rhea-AI Summary

Falcon Creek Capital Advisor LLC and related funds filed an amended beneficial ownership report on Cingulate Inc. common stock after acquiring shares on 03/24/2026 under a Purchase Agreement. Falcon Creek Capital Advisor reports beneficial ownership of 3,856,766 shares, representing 28.50% of Cingulate’s common stock, with shared voting and dispositive power over all such shares. Falcon Creek Technology Fund I holds 350,195 shares, or 2.59%, and Ginkgo Capital Global Fund SPC – Xtalpi AI Fund holds 3,506,571 shares, or 25.91%, each with shared voting and dispositive power. The reporting persons describe their holdings as venture and investment positions and state that, aside from the Purchase Agreement and related arrangements, they have no other contracts or understandings concerning Cingulate’s securities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.75%
Tags
ownership
-
EFFECT
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.22%
Tags
other
-
Rhea-AI Summary

Cingulate Inc. entered into an at-the-market equity sales agreement with A.G.P./Alliance Global Partners, allowing the company to sell common stock over time for aggregate gross proceeds of up to $100,000,000. A.G.P. will act as sales agent for these Nasdaq Capital Market transactions and receive a 3.0% commission on any shares sold.

Separately, stockholders at a special meeting approved issuing common stock upon conversion of Series A Convertible Preferred Stock and/or exercise of warrants under a January 27, 2026 securities purchase agreement, satisfying Nasdaq Listing Rule 5635(b) requirements. A related proposal to permit adjournment was also approved but ultimately not used.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.22%
Tags
current report
Rhea-AI Summary

Cingulate Inc. is registering common stock with an aggregate offering price of $100,000,000 for sale at-the-market through A.G.P./Alliance Global Partners pursuant to an At The Market Sales Agreement dated March 24, 2026.

The prospectus supplement states sales may be made on Nasdaq or other U.S. trading markets, A.G.P. will act as sales agent (entitled to a 3.0% commission) and the company intends to use net proceeds to advance CTx-1301 regulatory, development, manufacturing and commercialization activities and for general corporate purposes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.22%
Tags
prospectus

FAQ

How many Cingulate (CING) SEC filings are available on StockTitan?

StockTitan tracks 71 SEC filings for Cingulate (CING), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Cingulate (CING)?

The most recent SEC filing for Cingulate (CING) was filed on November 13, 2026.